Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sting agonists

- PMLiVE

AbbVie submits application for lymphoma therapy epcoritamab to EMA

Phase 2 trial showed an overall response rate of 63% and a complete response rate of 39%

- PMLiVE

AbbVie to acquire DJS Antibodies in $255m cash deal

The agreement includes DJS-002, an experimental drug for idiopathic pulmonary fibrosis

- PMLiVE

AbbVie’s Imbruvica bags FDA approval for paediatric patients with chronic graft versus host disease

The decision marks the first approved treatment for children with the condition under 12 years

- PMLiVE

AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn

The agreement will focus on drug discovery, development and commercialisation of neurological diseases

- PMLiVE

AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab

The INTERLINK-1 study assessed the combination drug candidate to treat patients with head and neck cancer

- PMLiVE

AbbVie submits migraine prevention drug to EMA for marketing authorisation

If approved, atogepant would be the first daily oral CGRP receptor antagonist migraine treatment for adults in Europe

- PMLiVE

AbbVie submits Parkinson’s disease therapy to FDA

The therapy offers a first-of-its-kind, 24-hour, continuous subcutaneous delivery

regeneron headquarters

Regeneron set to acquire Checkmate for approximately $250m

The deal is expected to be finalised in mid-2022

- PMLiVE

AbbVie’s Crohn’s disease drug given green light by MHRA

An estimated 217,000 people aged 16 and over live with the condition in the UK

- PMLiVE

AbbVie ends partnership with BioArctic to develop treatment for Parkinson’s disease

Results supporting phase 2 trials were presented at the International Congress of Parkinson’s Disease and Movement Disorders in September 2021

- PMLiVE

AbbVie’s Rinvoq accepted by SMC for atopic dermatitis

Scotland is the first nation in the UK to approve NHS access for the drug

- PMLiVE

AbbVie shares positive phase 3 results for migraine drug Qulipta

The impact of chronic migraines on patients can be debilitating

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links